# OnCo record gastric-pdl1-high (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/gastric-pdl1-high/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "gastric-pdl1-high" ;
  schema:name "PD-L1-high gastric cancer"@en ;
  schema:alternateName "PD-L1 CPS 5 or above gastric cancer"@en, "PD-L1-positive gastro-oesophageal adenocarcinoma"@en, "EBV-positive gastric cancer (PD-L1 high)"@en ;
  schema:description "PD-L1-high gastric cancer expresses the immune checkpoint protein PD-L1 on tumour and immune cells, and this is the group in which nivolumab or pembrolizumab added to chemotherapy clearly extends life. The benefit shrinks as the score falls, so regulators now restrict the antibodies to tumours with at least some PD-L1 expression."@en ;
  schema:url <https://onco.cc/cancers/gastric-pdl1-high/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Stomach_cancer> ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/34102137/>, <https://pubmed.ncbi.nlm.nih.gov/37875143/>, <https://en.wikipedia.org/wiki/Stomach_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/matterhorn/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/ideas/idea-biomarker-quadruplet-gastric/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/azd7789/> ;
  onco:standardOfCare <https://onco.cc/trials/checkmate-649/>, <https://onco.cc/trials/keynote-859/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/terms/cps/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/zolbetuximab/>, <https://onco.cc/terms/cps/>, <https://onco.cc/trials/matterhorn/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/flot/>, <https://onco.cc/trials/rainbow/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/paclitaxel/> .